Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BESTT: Belatacept, ATG, and Sirolimus in Living-donor Renal Transplants
NCT00346151Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2006
- Primary completion
- Feb 2010
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belatacept in renal transplant rejection (RTR), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Acute Rejection at 6-Months. Started Dec 2006; status: terminated.
02
Drugs
belatacept
03
Conditions
renal transplant rejection (RTR)
Beyond the preview
Go deeper on NCT00346151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00346151.